Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

TransCode Therapeutics, Inc. Common Stock (RNAZ)

Pharmaceutical Preparations

https://www.transcodetherapeutics.com

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat cancer through the intelligent design and effective delivery of RNA therapeutics. The company's therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian, and colon cancer, glioblastomas, and others.

6 LIBERTY SQUARE, #2382
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/09/2021

Market Cap

4,283,620

Shares Outstanding

630,000

Weighted SO

627,448

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

LABP --.--%

NEXI --.--%

ONCR --.--%

XBIO --.--%

RVPHW --.--%

EYEN --.--%

CGTX --.--%

KOD --.--%

IMMX --.--%

Beta

0.4590

Last Div

0.0000

Range

0.216-128.0

Chg

-0.0019

Avg Vol

1130440

Mkt Cap

4283620

Exch

NASDAQ

Country

US

Phone

857-837-3099

DCF Diff

-3.8471

DCF

7.6571

Div Yield

0.0000

P/S

5.6876

EV Multiple

-0.0665

P/FV

1.3230

Div Yield %

0.0000

P/E

-0.0977

PEG

-0.0010

Payout

0.0000

Current Ratio

1.2524

Quick Ratio

1.2524

Cash Ratio

0.9578

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1896.0750

CCC

-1896.0750

Gross Margin

0.2519

Op Margin

-23.6704

Pretax Margin

-23.7738

Net Margin

-23.7738

Eff Tax Rate

0.0085

ROA

-3.7112

ROE

-5.9747

ROCE

-13.4823

NI/EBT

1.0000

EBT/EBIT

1.0044

EBIT/Rev

-23.6704

Debt Ratio

0.0471

D/E

0.1719

LT Debt/Cap

0.0000

Total Debt/Cap

0.1467

Int Coverage

4.0190

CF/Debt

-67.9716

Equity Multi

3.6487

Rec Turnover

0.0000

Pay Turnover

0.1925

Inv Turnover

0.0000

FA Turnover

2.3081

Asset Turnover

0.1561

OCF/Share

-2.1906

FCF/Share

-2.1874

Cash/Share

0.4757

OCF/Sales

-20.5090

FCF/OCF

0.9985

CF Coverage

-67.9716

ST Coverage

-67.9716

CapEx Coverage

-683.1009

Div&CapEx Cov

-683.1009

P/BV

1.3230

P/B

1.3230

P/S

5.6876

P/E

-0.0977

P/FCF

-0.2777

P/OCF

-0.1133

P/CF

-0.1133

PEG

-0.0010

P/S

5.6876

EV Multiple

-0.0665

P/FV

1.3230

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 22, 16:45 TransCode Therapeutics Announces Closing of $7.25 Million Public Offering GlobeNewswire Inc. Jan 22, 16:45 TransCode Therapeutics Announces Closing of $7.25 Million Public Offering Zacks Investment Research Jan 19, 13:09 TransCode (RNAZ) Down 50% on Issue of New Common Stock GlobeNewswire Inc. Jan 18, 13:27 TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering GlobeNewswire Inc. Dec 12, 08:30 TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138 GlobeNewswire Inc. Nov 30, 14:53 TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules GlobeNewswire Inc. Nov 30, 14:53 TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules GlobeNewswire Inc. Oct 30, 16:33 TransCode Therapeutics Withdraws Public Offering

Revenue Product Segmentation